Helomics GeneFx Colon
Helomics announced today the official launch of GeneFx Colon, its multi-gene expression assay designed to identify colon cancer patients who are at a higher risk of recurrence within five years following initial surgery. The test is intended to help physicians make informed personalized treatment decisions about potentially adding adjuvant chemotherapy.
GeneFx Colon is performed on a small amount of tumor tissue and test results are available within the average time period for recovery post-surgery. The assay produces a binary result that categorizes patients as being at either high- or low-risk for a tumor recurrence within five years.